Researchers at Isis Pharmaceuticals Inc. and the University of California at San Diego have reported on a STAT3-targeting antisense oligonucleotide (ASO) that "produced robust antisense-mediated inhibition of target RNA molecules in tumors of several preclinical models, and demonstrated single-agent antitumor activity in several highly refractory cancer patients in a phase I dose-escalation study," corresponding author Robert MacLeod told BioWorld Today.